Harrow Shares Collapse, Another Opportunity?
Harrow, Inc. remains a compelling long-term and trading opportunity, especially attractive in the mid-$30s and lower $40s after recent pullbacks. HROW delivered strong Q4 2025 revenue growth of 33% YoY to $89.1M, with annual sales up 36% and adjusted EBITDA up 54% to $61.9M. Key product lines IHEEZO and VEVYE posted record results, while TRIESENCE relaunch is in early growth stages and ImprimisRx revenue is intentionally shifting toward higher-margin products.
Harrow (HROW) Misses Q4 Earnings Estimates
Harrow (HROW) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.25 per share a year ago.
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update
Harrow, Inc. continues to execute on its branded ophthalmic portfolio, with Vevye and Iheezo outperforming expectations and gaining market share. Despite a slight Q3 revenue miss and lowered 2025 guidance ($270M–$280M), operating leverage and commercial expansion underpin a robust growth outlook. Vevye's preferred formulary status and expanded coverage in 2026, alongside Iheezo's strong adoption, set up for accelerating revenue and margin improvement.
Harrow: Flirting With Missing 2025 Revised Guidance
Harrow may deliver $265M in 2025 revenue, potentially missing the low end of its revised $270M–$280M guidance. Recent Bloomberg data suggest strong growth in Iheezo and Vevye, but specialty and compounded segments face headwinds and one-time impacts. Considerable uncertainty exists due to data limitations and ASP uncertainty.
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS
Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in 2026, with potential for $2B+ by 2030. HROW's financials are accelerating: FCF/share expected at $4 in 2026 and $10 in 2027, with leverage rapidly declining and EBITDA margins rising.
Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential
Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per quarter by Q4 2027, leveraging recent acquisitions and biosimilar partnerships. Despite low profitability and modest cash reserves, HROW's experienced management, robust pipeline, and expanding market share support a bullish long-term outlook.
Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other
Harrow's recent debt refinancing, Melt Pharmaceuticals acquisition plans, and updated peak sales estimates reinforce the bullish thesis. Base case DCF modeling projects significant revenue growth through 2034, with relatively conservative assumptions on margins and product adoption. I reiterate a "Buy" rating for HROW stock, with ~88% upside to a $72.7 base case fair value, including some risk adjustments.
Harrow: Buy A Blend Of Value And Growth
I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, undertreated market, resulting in a 66% QoQ surge in prescriptions and rapid market penetration. Harrow's revenue growth is robust, averaging 43.7% YoY, with VEVYE expected to sustain momentum and push the company toward profitability.
Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock
Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet
The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
